
## Racer CC PLUS

#### New generation DES providing synergy of biodegradable polymer with microporous surface to enhance optimal performance



#### Less Polymeric Load Compared To Other DES

One million pores per cm<sup>2</sup> with average depth of 2 µm ensures optimum drug release with minimal use of polymer

Shellac Resin ensures better drug-polymer binding with negligible polymer flaking during stent expansion

Drug and Polymer are co-released in 6-9 months leaving behind bare metal stent surface

#### Abluminal Coating and Better Endothelialisation

Drug polymer matrix coated only on the abluminal side using patented stent coating technology for drug release only to target tissue

No polymer on the luminal side ensures healthy endothelialisation and reduces the incidence of stent thrombosis

	Stent length [mm] & Article numbe						
Length Ø [mm]							
	2.00 mm	2.25 mm	2.50 mm				
8.00	RRPP2008	RRPP2208	RRPP250				
12.00	RRPP2012	RRPP2212	RRPP251				
16.00	RRPP2016	RRPP2216	RRPP251				
18.00	RRPP2018	RRPP2218	RRPP251				
21,00	RRPP2021	RRPP2221	RRPP252				
24.00	RRPP2024	RRPP2224	RRPP252				
28.00	RRPP2028	RRPP2228	RRPP252				
32.00	RRPP2032	RRPP2232	RRPP253				
36.00							
40.00							
44,00							
48.00							

\* Please contact our Customer Care for available sizes

#### COMPLIANCE CHART

	Inflatio	on Press	sure (atr	n/bar/1	0° Pa).										
Balloon Ø [mm]						NP (Naminal Pressure)					RBP (Rated Burat Pressure)				
	6	7	8	9	10		12	13	14	15		17	18	19	20
Ø 2.00	1.83	1.87	1.90	1.93	1.96	2.00	2.03	2.06	2.10	2.13	2.16	2.20	2.23	2.26	2.29
Ø 2.25	2.08	2.11	2.14	2.18	2.21	2.25	2.28	2.31	2.35	2.38	2.42	2.45	2.48	2.52	2.55
Ø 2.50	2.33	2.36	2.40	2.43	2.47	2.50	2.53	2.57	2.60	2.64	2.67	2.70	2.74	2.77	2.81
Ø 2.75	2.58	2.61	2.65	2.68	2.71	2.75	2.78	2.81	2.85	2.88	2.91	2.94	2.98	3.01	3.04
Ø 3.00	2.81	2.85	2.89	2.92	2.96	3.00	3.04	3.07	3.11	3.15	3.18	3.22	3.26	3.29	3.33
Ø 3.50	3.29	3.34	3.38	3.42	3.46	3.50	3.55	3.59	3.63	3.67	3.71	3.76	3.80	3.84	3.88
Ø 4.00	3.75	3.80	3.85	3.90	3.95	4.00	4.06	4.11	4.16	4.21	4.26	4.31	4.36	4.41	4.46

#### **TECHNICAL DATA**

Cobalt Chromium Alloy (L605)			
Crossing Profile	0.035 / 0.889 mm	Entry Profile	0.016 / 0.406 mm
Strut Thickness	0.0027 / 68 µm (SV)	Proximal Shaft Diameter	1.9 F
	0.0031 / 79 µm (MV)	Distal Shaft Diameter	2.7 F
Metallic Surface Area	9.1 - 14.9%	Recommended Guide Wire	0.014"
Balloon Marker Material	Platinum / Iridium	Guiding Catheter	min. 5 F

Manufactured By: Translumina Therapeutics LLP Plot No. 12, Pharmacity, Selaqui, Dehradun 248 011 (Uttarakhand) India Drug Manufacturing License No.MFG/MD/2019/000227


Registered Office: Translumina Therapeutics LLP Ground Floor, Metro Tower, LSC MOR Land, New Rajinder Nagar, New Delhi 110 060 - India

Under Technological Collaboration With: Translumina GmbH Neue Rottenburger Strasse 50, D-72379 Hechingen, Germany










Customer Care No.: 011-28742874
Email: info@translumina.in
Visit www.translumina.in for more details.

Please refer to the Instructions for Use supplied with these devices for indications, contraindications, adverse effects, suggested procedures, warnings and precautions.

translumina











## Thin structural design concomitating with greater Deliverability

#### Ideal Strut Thickness


Racer CC Plusis designed with thinner struts to provide the healing advantage associated with minimal vessel injury and better endothelialisation

#### **Greater Deliverability**

Racer CC Plus with its ideal strut thickness offers optimal strength, flexibility and pushability thus ensuring precise deployment

#### **Enhanced Biocompatibility**


The trusted stent platform of Racer CC Plus has been steadily optimized with thinner struts and cell design offering better long-term outcomes






In this unique long term analysis at 10 years, Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy

# CLINICAL DATA OF EFFICACY & SAFETY








Comparison of clinical outcomes at 10 years in patients treated with new-generation BP-SES versus new-generation PP-EES versus early generation SES

## Unmatched Safety- In Complex Patients Subset

Long-term outcomes of biodegradable polymer v/s durable polymer DES in **patients with diabetes**: a pooled analysis of individual patient data from 3 randomised trials



At 4 years, Biodegradable Polymer DES Yukon showed significantly lower rates of stent thrombosis compared to durable polymer DES in patients with Diabetes Mellitus.




Secondary safety end point: definite or probable stent thrombosis

Long-term outcomes of biodegradable polymer v/s durable DES stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from 3 randomised trials

# **EuroIntervention**

At 4 years, biodegradable polymer DES compared to durable polymer SES demonstrated improved overall clinical outcome, reduced need for revascularisation as well as lower incidence of cardiac death or MI and reduced stent thrombosis in patients with STEMI.



Definite or probable stent thrombosis for the pooled population in each of the treatment groups. CI: confidence interval; HR: hazard ratio

\*As per Clinical data with SS stent using similar microporous surface and drug coating tec

